biomerica.png
Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer
30 août 2022 08h19 HE | Biomerica, Inc.
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development...
biomerica.png
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
14 avr. 2022 08h37 HE | Biomerica, Inc.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
biomerica.png
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
08 févr. 2022 06h39 HE | Biomerica, Inc.
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
Jasco-Logo-Blue-LRG-1170x369.jpg
Jasco Introduces New JascoPro Brand at International Builder Show
07 févr. 2022 08h00 HE | Jasco
OKLAHOMA CITY, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Connected home leader, Jasco, today unveils the new JascoPro Series brand at the International Builder Show in Orlando. Exclusive to the professional...
The Phytality Difference
Scientists and Nutritionists Collaborate on a New, Powerful Gut Health Dietary Supplement
04 févr. 2022 09h00 HE | Synesis Nutrition, Inc.
CAMBRIDGE, Wis., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Wisconsin-based nutrition and food chemistry experts at Synesis Nutrition, Inc. have collaborated on the development of a unique new product that...
biomerica.png
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million
16 déc. 2021 08h19 HE | Biomerica, Inc.
InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....
Featured Image for Rome Foundation
New Study Shows Patients With Irritable Bowel Syndrome and Functional Dyspepsia Experience High Levels of Bloating and Distension
09 déc. 2021 09h00 HE | Rome Foundation
RALEIGH, N.C., Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation Research Institute and Danone Nutricia Research have partnered on a study to look at the prevalence of bloating and distension in...
Featured Image for Rome Foundation
Rome Foundation Releases Clinical Criteria to Better Meet Needs of Patients
29 nov. 2021 09h00 HE | Rome Foundation
RALEIGH, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation has published a groundbreaking modification of the Rome IV diagnostic criteria of the Disorders of Gut Brain Interaction (DGBI -...
biomerica.png
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
30 août 2021 08h19 HE | Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
biomerica.png
Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression
11 août 2021 08h19 HE | Biomerica, Inc.
Hundreds of millions of people worldwide suffer from depression IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has...